Skip to main content
. 2022 May 20;80(7):1081–1090. doi: 10.1111/his.14642

Figure 3.

Figure 3

Flowchart showing the change in the diagnoses by the study pathologists in stage I [haematoxylin and eosin (H&E) only] and stage II (H&E + p53). BE‐IND, Barrett's oesophagus indefinite for dysplasia; HGD, high‐grade dysplasia; IMC, intramucosal cancer; LG, low‐grade dysplasia; NDBE, non‐dysplastic Barrett's oesophagus; P53‐IHC, P53 immunohistochemistry. [Colour figure can be viewed at wileyonlinelibrary.com]